

# Randomi- zed control- led trials for ISR

Clinical evidence SeQuent® SCB  
Preclinical work and randomized  
controlled trials

Randomized controlled trials for ISR

# Combined analysis of two parallel randomized trials of sirolimus-coated and paclitaxel-coated balloons in coronary in-stent restenosis lesions

First in Man Trials in Malaysia, Germany & Switzerland

Scheller B et al. Circ Cardiovasc Interv. 2022 Sep;15(9):e012305.

## Description

**Design:** Randomized | Prospective | Multicenter | Non-inferiority

**Indication:** DES-ISR

**Control:** SeQuent® Please NEO

**Primary endpoints:** LLL @ 6-month follow-up

**Secondary endpoints:**

- Procedural success

- MACE (TLR, cardiac death, TL-MI) @ 12-month follow-up
- Thrombosis rate @ 12-month follow-up
- Binary restenosis rate

**101 patients (DES-ISR)**

1:1 randomization

51 patients SeQuent® Please NEO		50 patients SeQuent® SCB	
Follow-up:			
1 month Clinical	6 months Angiographic	12 months Clinical	

## Results


Quantitative coronary angiography revealed no differences in baseline parameters.

**After 6 months, in-segment late lumen loss was:**

- $0.25 \pm 0.57$  mm in PCB group
- $0.26 \pm 0.60$  mm in SCB group

Mean difference between SCB and PCB was 0.01 (95% CI, -0.23 to 0.24).

**Non-inferiority** at a predefined margin of 0.35 was shown.



Angiographic patency: cumulative frequency distribution of in-segment late lumen loss determined by quantitative coronary angiography. Paclitaxel-coated balloon (PCB) versus sirolimus-coated balloon (SCB).

## Clinical follow-up at 1 year

	SCB Total	PCB Total	P value SCB vs. PCB
Number of patients (n [%])	50 (100)	51 (100)	
TLR (n [%])	8 (16)	5 (10)	0.389
Stent thrombosis (n [%])	0	1 (2)	1.000
Death (n [%])	1 (2)	1 (2)	1.000
MI (n [%])	0	1 (2)	1.000
MACE (n [%])	9 (18)	7 (14)	0.596

**Clinical events up to 12 months did not differ between the groups.**

## Conclusion

This **first-in man comparison of a novel SCB** with a crystalline coating showed **similar angiographic and clinical outcomes** in the treatment of coronary drug-eluting stent **in-stent restenosis compared with PCB.**